BR9505815A - Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica - Google Patents

Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica

Info

Publication number
BR9505815A
BR9505815A BR9505815A BR9505815A BR9505815A BR 9505815 A BR9505815 A BR 9505815A BR 9505815 A BR9505815 A BR 9505815A BR 9505815 A BR9505815 A BR 9505815A BR 9505815 A BR9505815 A BR 9505815A
Authority
BR
Brazil
Prior art keywords
synaptic
ischemic
agonist
patient
post
Prior art date
Application number
BR9505815A
Other languages
English (en)
Portuguese (pt)
Inventor
Jean-Pierre Geerts
Genevieve Motte
Edmond Differding
Jean-Pierre Henichart
Original Assignee
Ucb Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Sa filed Critical Ucb Sa
Publication of BR9505815A publication Critical patent/BR9505815A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C07D233/58—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR9505815A 1994-12-14 1995-12-13 Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica BR9505815A (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9425211.1A GB9425211D0 (en) 1994-12-14 1994-12-14 Substituted 1H-imidazoles

Publications (1)

Publication Number Publication Date
BR9505815A true BR9505815A (pt) 1998-01-06

Family

ID=10765918

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9505815A BR9505815A (pt) 1994-12-14 1995-12-13 Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica

Country Status (26)

Country Link
US (1) US5658938A (enExample)
EP (1) EP0717037A1 (enExample)
JP (1) JPH08208622A (enExample)
KR (1) KR960022474A (enExample)
CN (1) CN1054376C (enExample)
AR (1) AR002257A1 (enExample)
AU (1) AU693614B2 (enExample)
BG (1) BG63043B1 (enExample)
BR (1) BR9505815A (enExample)
CA (1) CA2165133A1 (enExample)
CZ (1) CZ327195A3 (enExample)
EE (1) EE9500064A (enExample)
FI (1) FI955927L (enExample)
GB (1) GB9425211D0 (enExample)
HU (1) HUT73980A (enExample)
IL (1) IL116325A (enExample)
IS (1) IS4311A (enExample)
MX (1) MX9505063A (enExample)
NO (1) NO305316B1 (enExample)
NZ (1) NZ280646A (enExample)
PL (1) PL311736A1 (enExample)
RO (1) RO113346B1 (enExample)
RU (1) RU2156239C2 (enExample)
SK (1) SK155095A3 (enExample)
TW (1) TW303362B (enExample)
ZA (1) ZA9510554B (enExample)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles
GB9520150D0 (en) * 1995-10-03 1995-12-06 Orion Yhtymae Oy New imidazole derivatives
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
US20030073850A1 (en) * 1998-08-07 2003-04-17 Altenbach Robert J. 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use
US6503935B1 (en) 1998-08-07 2003-01-07 Abbott Laboratories Imidazoles and related compounds as α1A agonists
US6388090B2 (en) 2000-01-14 2002-05-14 Orion Corporation Imidazole derivatives
IL152401A0 (en) 2000-05-08 2003-05-29 Orion Corp New polycyclic indanylimidazoles with alpha2 adrenergic activity
TW200930291A (en) * 2002-04-29 2009-07-16 Bayer Cropscience Ag Pesticidal heterocycles
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
FI20022007A0 (fi) * 2002-11-08 2002-11-08 Juvantia Pharma Ltd Oy Oromukosaalinen valmiste ja menetelmä sen valmistamiseksi
FI20022159A0 (fi) * 2002-12-05 2002-12-05 Orion Corp Uusia farmaseuttisia yhdisteitä
EP1981499A1 (en) * 2006-01-27 2008-10-22 F.Hoffmann-La Roche Ag Use of 2-imidazoles for the treatment of cns disorders
WO2008046756A1 (en) * 2006-10-19 2008-04-24 F. Hoffmann-La Roche Ag Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors
CA2666762C (en) * 2006-10-19 2014-12-30 F. Hoffmann-La Roche Ag Aminomethyl-4-imidazoles
EP2086959B1 (en) * 2006-11-02 2011-11-16 F. Hoffmann-La Roche AG Substituted 2-imidazoles as modulators of the trace amine associated receptors
MX2009005047A (es) * 2006-11-16 2009-05-25 Hoffmann La Roche 4-imidazoles sustituidos.
MX2009005920A (es) * 2006-12-13 2009-06-16 Hoffmann La Roche Nuevos 2-imidazoles como ligandos para receptores asociados con trazas de amina.
US20080146523A1 (en) 2006-12-18 2008-06-19 Guido Galley Imidazole derivatives
MX2009008255A (es) * 2007-02-02 2009-08-12 Hoffmann La Roche Nuevas 2-aminooxazolinas como ligandos taar1.
CN101702905A (zh) * 2007-02-13 2010-05-05 先灵公司 功能选择性α2C肾上腺素能受体激动剂
JP2010518161A (ja) * 2007-02-13 2010-05-27 シェーリング コーポレイション 機能選択性α２Ｃアドレナリン受容体アゴニストとしてのクロマン誘導体および類似体
CA2678072A1 (en) * 2007-02-13 2008-08-21 Schering Corporation Functionally selective alpha2c adrenoreceptor agonists
KR101222412B1 (ko) * 2007-02-15 2013-01-15 에프. 호프만-라 로슈 아게 Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
CN101687812A (zh) 2007-07-02 2010-03-31 弗·哈夫曼-拉罗切有限公司 对痕量胺相关受体(taar)具有良好亲和性的2-咪唑啉化合物
WO2009003867A1 (en) * 2007-07-03 2009-01-08 F. Hoffmann-La Roche Ag 4-imidazolines and their use as antidepressants
WO2009016048A1 (en) * 2007-07-27 2009-02-05 F. Hoffmann-La Roche Ag 2-azetidinemethaneamines and 2-pyrrolidinemethaneamines as taar-ligands
CN101765425A (zh) * 2007-08-02 2010-06-30 弗·哈夫曼-拉罗切有限公司 苯甲酰胺衍生物用于治疗cns障碍的用途
BRPI0814758A2 (pt) * 2007-08-03 2015-03-03 Hoffmann La Roche Piridinacarboxamida e derivados de benzamida como ligantes taar1
CL2008003553A1 (es) * 2007-12-05 2009-11-27 Grindeks Jsc Proceso para preparar atipamezol o clorhidrato de 5-(2-etil-2,3-dihidro-1h-inden-2-il)-1h-imidazol: y loa compuestos intermediarios considerados en el proceso
EP2257546B1 (en) 2008-02-21 2012-08-15 Merck Sharp & Dohme Corp. Functionally selective alpha2c adrenoreceptor agonists
US8242153B2 (en) * 2008-07-24 2012-08-14 Hoffmann-La Roche Inc. 4,5-dihydro-oxazol-2YL derivatives
CN102083805A (zh) * 2008-07-24 2011-06-01 弗·哈夫曼-拉罗切有限公司 4,5-二氢-唑-2-基衍生物
WO2010017120A1 (en) * 2008-08-04 2010-02-11 Schering Corporation Cyclopropylchromene derivatives as modulators of the alpha-2c receptor
WO2010042473A1 (en) 2008-10-07 2010-04-15 Schering Corporation Biaryl spiroaminooxazoline analogues as alpha2c adrenergic receptor modulators
US20100311798A1 (en) * 2009-06-05 2010-12-09 Decoret Guillaume 2-aminooxazolines as taar1 ligands
US8354441B2 (en) 2009-11-11 2013-01-15 Hoffmann-La Roche Inc. Oxazoline derivatives
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
US8673950B2 (en) 2010-11-02 2014-03-18 Hoffmann-Laroche Inc. Dihydrooxazol-2-amine derivatives
US8802673B2 (en) 2011-03-24 2014-08-12 Hoffmann-La Roche Inc Heterocyclic amine derivatives
US9073911B2 (en) 2011-06-09 2015-07-07 Hoffmann-La Roche Inc. Pyrazole derivatives
US9029370B2 (en) 2011-06-10 2015-05-12 Hoffmann-La Roche Inc. Substituted benzamide derivatives
RU2621050C2 (ru) 2012-01-12 2017-05-31 Ф. Хоффманн-Ля Рош Аг Гетероциклические производные в качестве рецепторов, ассоциированных со следовыми аминами (taars)
NO2895477T3 (enExample) 2012-09-14 2018-03-31
CA2879176C (en) * 2012-09-17 2020-10-27 F.Hoffmann-La Roche Ag Triazole carboxamide derivatives
WO2015165085A1 (en) 2014-04-30 2015-11-05 F.Hoffmann-La Roche Ag Morpholin-pyridine derivatives
CA2954098A1 (en) 2014-08-27 2016-03-03 F. Hoffmann-La Roche Ag Substituted azetidine derivatives as taar ligands
MX2016016190A (es) 2014-08-27 2017-03-08 Hoffmann La Roche Derivados de pirazino[2,1-a]isoquinolina sustituida para el tratamiento de trastornos del sistema nervioso central.
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｔａａｒのアゴニストとしての活性を有する５−エチル−４−メチル−ピラゾール−３−カルボキサミド誘導体
CN108777958B (zh) * 2016-03-17 2021-03-12 Fmc有限公司 将s-对映体转换成其消旋形式的方法
CN116496261B (zh) * 2023-03-09 2025-06-27 中国人民解放军军事科学院军事医学研究院 4-(1h)-咪唑类衍生物及其医药用途
CN118684628B (zh) * 2024-05-20 2025-06-17 中国人民解放军军事科学院军事医学研究院 取代二氢茚基咪唑类化合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6048972A (ja) * 1983-08-25 1985-03-16 Dai Ichi Seiyaku Co Ltd テトラヒドロナフタレン誘導体
GB2167408B (en) * 1984-11-23 1988-05-25 Farmos Oy Substituted imidazole derivatives and their preparation and use
GB8626287D0 (en) * 1986-11-04 1986-12-03 Ucb Sa Substituted 1h-imidazoles
GB2206880B (en) * 1987-07-16 1991-04-24 Farmos Oy Optical isomers of an imidazole derivative
US5151526A (en) * 1990-10-11 1992-09-29 The United States Of America As Represented By The Secretary Of The Army 4-[1-(1-naphthalenyl)ethyl]-1H-imidazole, method of making and use as an anesthetic
JPH04210680A (ja) * 1990-12-01 1992-07-31 Nissan Chem Ind Ltd イミダゾール誘導体および植物生長調節剤
GB9425211D0 (en) * 1994-12-14 1995-02-15 Ucb Sa Substituted 1H-imidazoles

Also Published As

Publication number Publication date
AU4036895A (en) 1996-06-20
NO955034D0 (no) 1995-12-12
FI955927A0 (fi) 1995-12-11
FI955927A7 (fi) 1996-06-15
HUT73980A (en) 1996-10-28
RU2156239C2 (ru) 2000-09-20
SK155095A3 (en) 1997-02-05
KR960022474A (ko) 1996-07-18
CN1133837A (zh) 1996-10-23
NZ280646A (en) 1996-08-27
IL116325A (en) 1999-10-28
GB9425211D0 (en) 1995-02-15
AU693614B2 (en) 1998-07-02
EE9500064A (et) 1996-06-17
MX9505063A (es) 1997-01-31
NO955034L (no) 1996-06-17
JPH08208622A (ja) 1996-08-13
US5658938A (en) 1997-08-19
ZA9510554B (en) 1996-06-13
PL311736A1 (en) 1996-06-24
TW303362B (enExample) 1997-04-21
CA2165133A1 (en) 1996-06-15
CN1054376C (zh) 2000-07-12
EP0717037A1 (fr) 1996-06-19
BG100208A (bg) 1996-07-31
AR002257A1 (es) 1998-03-11
RO113346B1 (ro) 1998-06-30
IS4311A (is) 1996-06-15
HU9503549D0 (en) 1996-02-28
FI955927L (fi) 1996-06-15
NO305316B1 (no) 1999-05-10
BG63043B1 (bg) 2001-02-28
CZ327195A3 (en) 1996-07-17
IL116325A0 (en) 1996-03-31

Similar Documents

Publication Publication Date Title
BR9505815A (pt) Composto processos para a preparação do mesmo e para obter um efeito anti-isquêmico e anti-hipertensivo e para produzir atividade agonista 2 pré-sináptica e antagonista 1 pós-sináptica em um paciente e composição farmacêutica
FI903845A7 (fi) Reniini-inhibiittoreita, menetelmä niiden valmistamiseksi ja niiden käyttö lääkkeissä
BR9611410A (pt) Método e composição farmacêutica para regular a concentração de lipídios
DE69801045D1 (de) Pharmazeutische zusammensetzung zur oralen verabreichung von einem n-piperidin-3-pyrazolcarboxamid-derivat, dessen salzen und deren solvaten
BR9001586A (pt) Cupula destinada a ser fixada sem cimento para protese total da anca e elemento para sua colocacao no cotilo de um paciente
CY2009018I2 (el) Φαρμακευτικη συνθεση περιλαμβανουσα πιογλιταζονη και γλιμεπιριδη για χρηση στην θεραπεια του διαβητη
BR9006924A (pt) Formulacao para tratamento de sintomas e doencas,uso de formulacao para o tratamento de sintomas e doencas,metodo para o tratamento de sintomas e doencas,distribuicao de agentes medicinais e terapeuticos para o tratamento de sintomas e doencas e combinacao para administracao em mamiferos
IT1247784B (it) Composizione e metodo per la riduzione dell'appetito
FI891590A7 (fi) Ihoa kosteuttava koostumus ja menetelmä sen valmistamiseksi
PT929516E (pt) Derivados da benzamidina e sua utilizacao em composicoes farmaceuticas com efeito antagonista da ltb4
NO20016068D0 (no) Anvendelse av oksypurin-nukleosider for fremstilling av et farmasöytisk preparat for redusering av inflammasjon i et dyr
NO942303D0 (no) Farmasöytisk preparat, samt fremgangsmåte for fremstilling derav
ATE204177T1 (de) Verwendung von substanz p antagonist im pharmazeutischer zusammensetzung
FI950439A7 (fi) 3'-atsido-3'-deoksitymidiinin kontrolloidusti vapauttavat farmaseuttis et valmisteet ja käyttömenetelmät
FI973040L (fi) Rasemointimenetelmä käytettäväksi levobupivakaiinin ja siihen läheisesti liittyvien piperidiinikarboksanilidipuudutusaineiden valmistuksessa
FI945694L (fi) Substituoiden triatsolin sulfaattisuola, sen farmaseuttisia koostumuksia ja niiden käyttö terapiassa
ITMI922779A1 (it) Antagonisti delle tachichinine, procedimento per la loro preparazione e loro impiego in formulazioni farmaceutiche
NO974057L (no) Bisykliske takykinin-antagonister, fremstilling derav og deres anvendelse i farmasöytisk sammensetning
ZA895271B (en) ((4-piperidyl)methyl)-2,3-dihydro-1h-isoindole and-2,3,4,5-tetrahydro-1h-benzazepine derivatives,their preparation and their application in therapy
GB8917527D0 (en) Oxaza heterocycles and their use in pharmaceutical compositions
FI892963A7 (fi) Farmaseuttinen koostumus ja menetelmä sen valmistamiseksi
IT1142304B (it) Derivati dell'indano loro preparazione e loro applicazione in terapeutica
FR2505825B1 (fr) Derives d'isoprenylamine et leur utilisation dans des compositions pharmaceutiques
EE9400182A (et) Peptiidühendid, nende kasutamine, valmistamismeetod ja farmatseutiline segu
BE885586A (fr) Nouveaux derives d'acides alcanoiques utiles notamment comme medicaments diuretiques, compositions therapeutiques et formes pharmaceutiques les contenant

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
FA8 Dismissal: dismissal - article 36, par. 1 of industrial property law